Biperiden HCl (Synonyms: NSC 84989, NSC 170950) |
| Catalog No.GC10621 |
Le chlorhydrate de bipéridène (KL 373) est un antagoniste non sélectif des récepteurs muscariniques qui se lie de manière compétitive aux récepteurs muscariniques M1, inhibant ainsi l'acétylcholine et améliorant la signalisation de la dopamine dans le système nerveux central.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1235-82-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Biperiden HCl is an anticholinergic drug [1].
As an anticholinergic drug, biperiden is first used in the treatment of Parkinson's disease. It is a competitive antagonist of muscarinic receptor. It has been believed that in the patients of PD, a reduction of intranigral dopamine concentrations results in a relative imbalance between the dopaminergic and cholinergic neurological pathways. The anticholinergics can correct the imbalance through reducing the degree of neurotransmission mediated by neostriatal acetylcholine. Biperiden is also used to treat extrapyramidal side effects of antipsychotic drugs. In addition, the misuse of biperiden causing delirium has been reported in several clinical settings [1, 2].
References:
[1] Brocks D R. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci, 1999, 2(2): 39-46.
[2] Espi Martinez F, Espi Forcen F, Shapov A, et al. Biperiden Dependence: Case Report and Literature Review. Case reports in psychiatry, 2012, 2012.
| Animal experiment : | |
|
Animal models |
Male Lister Hooded rats model; |
|
Dosage form |
3, and 10 mg/kg; intraperitoneal injection; for 90 min; or 4 mg, oral administration |
|
Applications |
Biperiden HCl acted as cognition impairer in rats and Biperiden (10 mg/kg) induced side-effects, with rats taking more time to start the task [1]. Moreover, oral doses of 4 mg of Biperiden HCl reached a Cmax of approximately 4 ng/mL [2]. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: 1. Szczodry, O., van der Staay, F. J. and Arndt, S. S. (2014) Modelling Alzheimer-like cognitive deficits in rats using biperiden as putative cognition impairer. Behav Brain Res. 274, 307-311 2. Brocks, D. R. (1999) Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 2, 39-46 | |
| Cas No. | 1235-82-1 | SDF | |
| Synonymes | NSC 84989, NSC 170950 | ||
| Chemical Name | 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol;hydrochloride | ||
| Canonical SMILES | C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O.Cl | ||
| Formula | C21H30ClNO | M.Wt | 347.92 |
| Solubility | ≥ 8.7mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8742 mL | 14.3711 mL | 28.7422 mL |
| 5 mM | 574.8 μL | 2.8742 mL | 5.7484 mL |
| 10 mM | 287.4 μL | 1.4371 mL | 2.8742 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *